EvaluatePharma®

Adverse Events

A collaboration with AdverseEvents, Inc.

AdverseEvents
REDEFINING DRUG SAFETY

Evaluate™

Adverse Events

Adverse events submitted to FDA through the FDA Adverse Event Reporting System (FAERS) can provide critical insight into the emerging adverse event profile of marketed drugs.

Evaluate have collaborated with AdverseEvents, Inc. (AEI) to provide a truly unique service that combines AEI's high quality FAERS post-approval safety data and proprietary analyses with the power of EvaluatePharma® commercial intelligence and evaluation tools. This resource can be used to understand emerging adverse event trends, conduct comparative safety assessments of drugs through access to statistical severity rankings and the ability to predict future regulatory action. This insight can finally be leveraged in commercial assessments, licensing/M&A, competitive positioning, clinical trial designs and safety monitoring.

Gain **competitive advantage** with fast and easy access to FAERS post-approval safety data, all integrated within EvaluatePharma® to help you manage risk and optimize R&D and commercial performance.

Key Features:

- Standardized, high quality FAERS data with up-to-date FOIA (Freedom of Information Act) requests
- Proprietary scores of relative safety and signals of potential future drug label risks
- Inclusion of adverse event incidence rates per 100,000 patients treated
- Classification of adverse events as 'on-label' or 'non-label' depending on whether they appear on the current drug label
- Adverse events defined as serious or non-serious and exclusion of disease-related adverse events
- Screen for class effects across multiple drugs from similar groups
- Screen for patient demographics susceptibility to adverse event
- Comparisons by Indication, Pharmacological Class and EphMRA codes
- Company portfolio and product safety profiles for comparative benchmarking
- Custom analytical services performed by credentialed experts

Key Benefits:

- Accessible, Actionable FAERS
- Optimised Positioning & Labeling
- Risk Assessment in Investment Decisions
- Essential Competitive Intelligence
- Insights for Clinical Trial Planning
- Proactive Product Warning Signals

Commercial Insights Teams

Provide your internal customers with product safety insights that are easy to interpret and incorporate into internal models.

Business Development Teams

Optimise in-licensing and acquisitions by assessing risk through comparative benchmarking using the same FDA adverse events reports regulators see.

Clinical Trial Project Teams

Design clinical trials with safety in mind incorporating enhanced safety monitoring plans and risk mitigation strategies that save R&D costs.

Launch, Brand and Marketing Teams

Assess your product's safety profile and label against peers to optimize product positioning and manage product risk.

Pharmacovigilance Teams

Integrate easy-to-access FAERS data into your existing Pharmacovigilance programme to identify safety problems and manage risk across product lifecycle.

Request a demo today

Download our Whitepaper

AE2015

Evaluate™

Download our Whitepaper at:
www.evaluategroup.com/AdverseEvents

Established in 1996, Evaluate Ltd is the trusted leader in high quality life science sector analysis and consensus forecasts to 2020. Evaluate's team of expert analysts transform life science information into insights so companies can perform well.

EvaluatePharma® delivers exclusive consensus sales forecasts and trusted commercial insight into biotech and pharmaceutical performance.
@EvaluatePharma

EvaluateMedTech® sets a new standard in commercial analysis and consensus forecasts of the global medical device and diagnostic industry.
@EvaluateMedTech

EvaluateClinical Trials® delivers unique clinical trial intelligence expertly curated to efficiently analyse the global clinical trial landscape.
@EPClinicalTrial

EP Vantage an award winning editorial team, provides daily commentary and analysis with fresh perspectives and insight into current and future industry trends.
@EPVantage

The Evaluate services enable the life science community to make sound business decisions about value and opportunity.

AdverseEvents, Inc. is a California-based healthcare informatics company that improves patient safety and reduces systemic healthcare costs through the comprehensive analysis of post-marketing drug side effect data. Utilizing data-mining and analysis technology, through its proprietary RxSuite™ of analytics, AEI makes post-marketing drug safety data accessible, actionable, and predictable. For more information please visit:

www.adverseevents.com @adverseevent

AdverseEvents
REDEFINING DRUG SAFETY

www.evaluate.com

Evaluate Headquarters
Evaluate Ltd.
11-29 Fashion Street
London E1 6PX
United Kingdom
T +44 (0)20 7377 0800
F +44 (0)20 7539 1801

Evaluate North America
EvaluatePharma USA Inc.
15 Broad Street, Suite 401
Boston, MA 02109, USA
T +1 617 573 9450
F +1 617 573 9542

Evaluate Japan
EvaluatePharma Japan K.K.
Kyodo Tsushin Kaikan 2F
2-2-5 Toranomon Minato-ku
Tokyo 105-0001, Japan
T +81 (0)80 1164 4754